Short answer
GERON CORP (GERN) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $57M (up 17.2% year over year) with net income of −$17M.
Q2 2026 key financials · XBRL
- Revenue
- $57M
- +17.2% YoY · +10.9% QoQ
- Net income
- −$17M
- −1.9% YoY · −358.0% QoQ
- Operating margin
- -21.7%
- EPS (diluted)
- −$0.02
- +0.0% YoY · −100.0% QoQ
Source: XBRL data from the GERON CORP (GERN) Q2 2026 10-Q on SEC EDGAR. USD.
GERON CORP Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No profitability, margin, segment, or product-line figures provided
- Forward-looking statements subject to risks, uncertainties, and materially different actual results
Risk Factors
- New regulatory risk: EU pricing and reimbursement rules may limit RYTELO coverage and commercialization following March 2025 EU authorization
- Most material update: revised U.S. commercial strategy targeting high-volume accounts after revenue reached $57.5 million in Q2 2026
- Compliance risk: healthcare-law violations could trigger criminal sanctions, civil penalties, and federal-program exclusion
- Operational risk: limited experience scaling RYTELO commercialization may constrain near-term sales growth
- Financial risk: additional capital may be required to continue RYTELO development and commercializationcuntegn
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other GERON CORP quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.